Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation
Research output: Contribution to journal › Review › Research › peer-review
Documents
- Fulltext
Final published version, 849 KB, PDF document
The introduction of targeted therapies to the field of oncology has prolonged the survival of several tumor types. Despite extensive research and numerous trials, similar outcomes have unfortunately not been realized for glioblastoma. For more than 15 years, the standard treatment of glioblastoma has been unchanged. This review walks through the elements that have challenged the success of previous trials and highlight some future promises. Concurrently, this review describes how institutions, through a multimodal and comprehensive strategy with 4 essential components, may increase the probability of finding a meaningful role for targeted therapies in the treatment of glioblastoma. These components are (1) prudent trial designs, (2) considered drug and target selection, (3) harnessed real-world clinical and molecular evidence, and (4) incorporation of translational research.
Original language | English |
---|---|
Article number | vdac157 |
Journal | Neuro-Oncology Advances |
Volume | 4 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
- glioblastoma, real-world evidence, targeted treatment, translational research, trial design
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 335697875